Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML

NCT03504410 is registered in ClinicalTrials.gov with Cornerstone Pharmaceuticals as lead sponsor.

NCT NCT03504410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03504410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Lead sponsor
Cornerstone Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
November 12, 2018
Completion date
January 19, 2022
Enrollment
200 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory acute myeloid leukemia